Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.

ABSTRACT: Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths in men in the United States. The treatment paradigm for prostate cancer has evolved with the emergence of a variety of novel therapies which have improved survival; however, treatment-related toxicities are abundant and durable responses remain rare. Immune checkpoint inhibitors have shown modest activity in a small subset of patients with prostate cancer and have not had an impact on most men with advanced disease. The discovery of prostate-specific membrane antigen (PSMA) and the understanding of its specificity to prostate cancer has identified it as an ideal tumor-associated antigen and has revived the enthusiasm for immunotherapeutics in prostate cancer. T-cell immunotherapy in th

SUBMITTER: Zarrabi KK 

PROVIDER: S-EPMC10285603 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature